Metabolic Research Market

Hepcidin

The 25-amino-acid liver hormone that sets systemic iron levels by binding and degrading the iron exporter ferroportin, tested in two phase 2 trials as LJPC-401 and never approved as a drug anywhere.

Iron MetabolismFerroportinHemochromatosisPeptide HormoneNot FDA Approved

Also referenced as: Hepcidin-25, LEAP-1, LJPC-401, Hepcidin acetate

Also appears in: Hormone · Immune

Public product evidence No certificate records are bound to a tracked Hepcidin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Hepcidin product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Metabolic signaling research

Primary research area: Metabolic. Also surfaces under Hormone · Immune for browsing and discovery.

Body systems
Hormones · Systemic · Immune

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
4

Hepcidin-25, LEAP-1, LJPC-401, Hepcidin acetate

Signal depth
Low

No FDA label signal · 100 trials · 361 PubMed results

Promising

Hepcidin has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Hepcidin has 14 name-matched clinical trials (2 international) (highest phase: Phase 4) and 361 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet. Note: 1 retracted publication in the literature.

🌍 2 international trials ⚠ 1 retracted publication
Human data
Phase 3
Trial quality
Randomized
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Hepcidin?

Hepcidin is a 25-amino-acid peptide hormone made in the liver and the master regulator of how much iron enters human plasma. It is encoded by the HAMP gene on chromosome 19 as an 84-residue prepropeptide that is cleaved to the mature circulating form, hepcidin-25, with the sequence Asp-Thr-His-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys-Cys-His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Lys-Thr, a formula of C113H170N34O31S9 and a molecular weight of about 2,789 Da. Eight of its 25 residues are cysteines, joined by four disulfide bonds into a tightly folded, amphipathic distorted beta-sheet hairpin; the first NMR structure placed an unusual vicinal disulfide bridge at the turn (Hunter et al., Journal of Biological Chemistry, 2002), and the connectivity was later corrected to Cys1-Cys8, Cys3-Cys6, Cys2-Cys4 and Cys5-Cys7 by a group using NMR, mass spectrometry and a co-crystal with an antibody fragment (Jordan et al., Journal of Biological Chemistry, 2009).

The molecule was found twice within a year. One team isolated it from human blood ultrafiltrate as a cysteine-rich antimicrobial peptide and called it LEAP-1, for liver-expressed antimicrobial peptide (Krause et al., FEBS Letters, 2000). A second team purified it from urine, found three N-terminally truncated forms of which the 20-residue and 25-residue species predominate, and named it hepcidin for its hepatic origin and antimicrobial properties (Park et al., Journal of Biological Chemistry, 2001). Hepcidin-20 is a shorter circulating fragment, and serial deletion of N-terminal residues progressively reduces ferroportin-degrading activity until it is lost at five residues (Nemeth et al., Blood, 2006).

Hepcidin has no approved medicinal product in any country and is sold only as a research reagent. The one marketed drug on this axis is a separate molecule: the hepcidin mimetic rusfertide, approved by the FDA on August 28, 2026 under NDA 220605, is a modified peptide rather than hepcidin itself.

How it works

  • Binds the iron exporter ferroportin and removes it from the cell surface. Ferroportin is the only known cellular iron exporter in mammals. Hepcidin binds it, after which the transporter is internalized and degraded, so dietary iron absorption and iron release from macrophage stores both fall (Nemeth et al., Science, 2004). Loss of hepcidin produces tissue iron overload; excess hepcidin produces hypoferremia and the anemia of inflammation.
  • Blocks iron transit directly, not only by degrading the transporter. Cryo-EM structures of ferroportin in lipid nanodiscs show hepcidin bound in the transporter’s central cavity in an outward-open state, fully occluding the iron efflux pathway, with the hepcidin C-terminus contacting a divalent metal in the transporter’s C domain and hepcidin affinity rising about 80-fold in the presence of iron, so iron-loaded transporters are preferentially targeted (Billesbølle et al., Nature, 2020). Occlusion without endocytosis was demonstrated in cells expressing an endocytosis-defective transporter mutant, in Xenopus oocytes and in mature human red blood cells (Aschemeyer et al., Blood, 2018).
  • Sits downstream of iron status, inflammation and erythropoietic demand. Liver iron signals through bone morphogenetic protein 6 and SMAD transcription factors to raise HAMP transcription, and Bmp6-null mice show reduced hepcidin expression and tissue iron overload resembling hereditary hemochromatosis (Andriopoulos et al., Nature Genetics, 2009). Interleukin-6 is necessary and sufficient to induce hepcidin during inflammation, which is the mechanism of the hypoferremia seen in infection and chronic inflammatory disease (Nemeth et al., Journal of Clinical Investigation, 2004). In the opposite direction, erythroblasts responding to erythropoietin secrete erythroferrone, which suppresses hepcidin after blood loss and is greatly increased in a mouse model of thalassemia intermedia (Kautz et al., Nature Genetics, 2014), and the hepatic protease encoded by TMPRSS6 restrains hepcidin, so loss-of-function mutations cause iron-refractory iron deficiency anemia (Finberg et al., Nature Genetics, 2008).
  • Retains the antimicrobial activity it was discovered for. Synthetic LEAP-1 inhibited Gram-positive and Gram-negative bacteria and yeast in radial diffusion assays (Krause et al., FEBS Letters, 2000), and urinary hepcidins showed antifungal activity against Candida albicans and Aspergillus species and antibacterial activity against Escherichia coli, staphylococci and group B Streptococcus (Park et al., Journal of Biological Chemistry, 2001). The physiological contribution of direct killing is considered small next to iron withholding, which starves microbes of iron.

Research status

Human genetics established the hormone’s role before any drug work. Two families with severe juvenile hemochromatosis carried HAMP mutations, showing that hepcidin deficiency alone causes human iron overload (Roetto et al., Nature Genetics, 2003). Mice lacking hepcidin expression developed severe tissue iron overload (Nicolas et al., Proceedings of the National Academy of Sciences, 2001), and the gene was overexpressed in iron-loaded mouse liver (Pigeon et al., Journal of Biological Chemistry, 2001).

Phase 2 in hereditary hemochromatosis (NCT03395704). A randomized, single-blind, placebo-controlled trial of LJPC-401, a synthetic human hepcidin given by subcutaneous injection, enrolled 70 adults with hereditary hemochromatosis between November 29, 2017 and October 28, 2019; 34 received hepcidin and 35 received saline. In the prespecified analysis population of 21 treated and 28 placebo patients, the mean change in transferrin saturation over 16 weeks was −32.8% with hepcidin against −2.5% with placebo (p less than 0.0001), meeting the primary endpoint. Treated patients needed a mean of 0.52 phlebotomies against 2.96 on placebo. Serum ferritin, a secondary endpoint, did not separate, falling 18.0% against 18.5%. Safety was the weaker part of the record: 317 treatment-emergent adverse events were reported across 34 treated patients against 101 across 35 placebo patients, driven by injection site reactions such as erythema in 17 treated patients and none on placebo. Two patients in each arm had serious adverse events, including one case of hyponatremia on treatment, and nausea affected 4 treated patients against 1 on placebo.

Phase 2 in transfusion-dependent beta thalassemia (NCT03381833). An open-label, randomized, parallel-group trial at 22 sites in eight countries enrolled 84 patients aged 14 and over with cardiac iron loading on T2* magnetic resonance imaging despite at least a year of stable chelation. One group added LJPC-401 to chelation immediately and the other after 26 weeks of chelation alone, with change in cardiac T2* at 26 weeks as the primary endpoint. The trial was terminated early for lack of efficacy on the basis of interim endpoint analyses, with a primary completion date of December 3, 2019, and no results were posted. On November 25, 2019 the sponsor announced that it would reassess continued development of LJPC-401 in light of the mixed results of the two studies. The registry lists no later trial of LJPC-401, and no sponsor has registered an interventional trial of hepcidin-25 itself since.

Why the native hormone was displaced by mimetics. Natural hepcidin is prohibitively expensive for human use and has unfavorable pharmacologic properties, so a UCLA group mapped the hepcidin-ferroportin interface and showed that the 7 to 9 N-terminal residues plus a single thiol cysteine retain activity, yielding protease-resistant minihepcidins that lowered serum iron in mice comparably to parenteral native hepcidin (Preza et al., Journal of Clinical Investigation, 2011) and prevented iron overload in hepcidin-deficient mice (Ramos et al., Blood, 2012). That line of work led to rusfertide, whose phase 2 trial controlled erythrocytosis in polycythemia vera (Kremyanskaya et al., New England Journal of Medicine, 2024) and which is now the only approved hepcidin mimetic.

Blocking hepcidin has been tried repeatedly for anemia. Lexaptepid pegol, a mirror-image oligonucleotide that sequesters hepcidin, reversed inflammation-induced anemia in cynomolgus monkeys (Schwoebel et al., Blood, 2013) and prevented hypoferremia in a human endotoxemia model, where serum iron rose 15.9 µmol/L in 24 treated volunteers while falling 8.3 µmol/L in controls (van Eijk et al., Blood, 2014), with a healthy-subject safety study following (Boyce et al., British Journal of Pharmacology, 2016); its 12-patient cancer anemia trial (NCT01691040) and 33-patient dialysis trial (NCT02079896) completed in 2013 and 2015 without posted results or further development. PRS-080, an engineered Anticalin protein with picomolar affinity for hepcidin, suppressed hepcidin and mobilized iron in 48 healthy volunteers and 24 hemodialysis patients without dose-limiting toxicity but did not consistently change hemoglobin or reticulocytes (Renders et al., PLoS One, 2019), and an 11-patient phase 2a study in anemic kidney disease (NCT03325621) was its last registered trial. More recent work targets the pathway rather than the hormone: the anti-hemojuvelin antibody DISC-0974 lowered serum hepcidin by nearly 75% at the highest dose and raised serum iron in a phase 1 study of 42 healthy participants (Novikov et al., Journal of Clinical Pharmacology, 2024), while the antisense drug sapablursen raises endogenous hepcidin by reducing TMPRSS6 and missed its primary and secondary endpoints in 29 patients with non-transfusion-dependent thalassemia intermedia (Taher et al., Blood Advances, 2026).

Measurement remains the most common use. Most registered hepcidin studies are observational or nutritional, using serum or urinary hepcidin as a biomarker of iron status and inflammation rather than administering the peptide. Absolute values differ substantially between assays, with a 28.6% intermeasurement coefficient of variation across eleven procedures (van der Vorm et al., Clinical Chemistry, 2016), so results from different platforms are not directly comparable.

Common dosage forms

  • No approved presentation. There is no licensed hepcidin product in the US or any other jurisdiction, so no vial, pen, ampoule or tablet strength exists on any market.
  • Investigational solution for injection. LJPC-401 was supplied to trial sites as a solution for subcutaneous injection in single-use vials of 5 mg/mL and 10 mg/mL, administered under clinical supervision; it was never marketed.
  • Research-grade peptide. Hepcidin-25 is distributed to laboratories as a lyophilized powder, usually as the acetate or trifluoroacetate salt in milligram vials.

Key considerations

  • Regulatory status. The Research Market status reflects the absence of an approved hepcidin product in the US or abroad and the end of the only registered clinical program in 2019. The two phase 2 trials were run by a single sponsor, one met a laboratory endpoint and the other was stopped for futility, and no hepcidin-25 trial has been registered since.
  • The approved drug on this axis is a different molecule. Rusfertide is a modified peptide mimetic, not hepcidin, and its approval says nothing about the native hormone’s own safety or efficacy. The antagonist programs are also distinct molecules: an oligonucleotide, an Anticalin protein, an antibody and an antisense drug, none of them approved.
  • Direction of effect decides the disease. Too little hepcidin causes iron overload and too much causes the anemia of inflammation, so agonists and antagonists of the same axis are developed for opposite conditions and results from one direction do not transfer to the other.
  • The human efficacy signal was a laboratory one. A fall in transferrin saturation with fewer phlebotomies over 16 weeks is a pharmacodynamic result, not an outcome benefit, and it came with ferritin unchanged, cardiac iron unimproved in thalassemia and about three times as many adverse events on treatment as on placebo.
  • Naming. Hepcidin, hepcidin-25, LEAP-1 and the gene product of HAMP denote the same molecule, LJPC-401 was its clinical development code, and hepcidin-20 is a shorter N-terminally truncated form with reduced activity. Rusfertide, lexaptepid pegol, PRS-080, DISC-0974 and sapablursen are separate compounds that act on the hepcidin axis and are not alternative names for the hormone.